ID
22466
Beschrijving
Study ID: 100273 Clinical Study ID: HS2100273 Study Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter 60-Day Study Comparing the Efficacy of Valtrex 1 Gram Once Daily vs. Placebo Once Daily in Reducing Viral Shedding in Immunocompetent Subjects with Recurrent HSV-2 Genital Herpes Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Completed Generic Name: valaciclovir Trade Name: ZELITREX,Valtrex,RAPIVIR,Novirus Study Indication: Herpes Genitalis Visit description: Study Visit 1 / Day 15
Trefwoorden
Versies (2)
- 05/06/2017 05/06/2017 -
- 06/06/2017 06/06/2017 -
Geüploaded op
5 de junho de 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Efficacy of Valtrexin in Subjects with Recurrent HSV-2 Genital Herpes Study Visit 1
Efficacy of Valtrexin in Subjects with Recurrent HSV-2 Genital Herpes Study Visit 1
Similar models
Efficacy of Valtrexin in Subjects with Recurrent HSV-2 Genital Herpes Study Visit 1
C0008952 (UMLS CUI-2)
C0008952 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,2])
C0034897 (UMLS CUI [1,2])
C0008952 (UMLS CUI [1,2])
C0019348 (UMLS CUI [2,1])
C0008952 (UMLS CUI [2,2])